TY - JOUR
T1 - Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis
T2 - How to Decide Which Treatment Is Right for Your Patients
AU - Ahn, Jiyoung
AU - Grinich, Erin E.
AU - Choi, Yusung
AU - Guttman-Yassky, Emma
AU - Simpson, Eric L.
N1 - Funding Information:
Conflicts of interest: J. Ahn reported receiving research funds from Pfizer during the conduct of the study. E. E. Grinich declares no relevant conflicts of interest. Y. Choi reported receiving research funds from Eli Lilly and Company during the conduct of the study. E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie , Celgene , Eli Lilly , Janssen , Medimmun e/ AstraZeneca , Novartis , Pfizer , Regeneron , Vitae , Glenmark , Galderma , Asana , Innovaderm , Dermira , and UCB ; she is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, AbbVie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. E. L. Simpson reports grants from Eli Lilly , Incyte , Kyowa Hakko Kirin , Leo Pharmaceutical , Merck , Pfizer , and Regeneron , and personal fees from AbbVie, Dermira, Eli Lilly, Forte Bio Rx, Genzyme, Incyte, Leo, Pfizer, Regeneron, and Sanofi-Genzyme.
Publisher Copyright:
© 2021
PY - 2021/4
Y1 - 2021/4
N2 - The evolving discoveries in atopic dermatitis (AD) broaden our understanding of the pathogenesis of the disease and, above all, enable better management for patients. Dupilumab was the first biologic for AD, and since its approval, many new treatments have emerged in both late- and early-stage clinical trials. These trials have led to a further understanding of the pathogenesis of AD and to the identification of additional potential therapeutic targets. This review will highlight the emerging therapies and provide approaches on how to choose the right treatment for your patients.
AB - The evolving discoveries in atopic dermatitis (AD) broaden our understanding of the pathogenesis of the disease and, above all, enable better management for patients. Dupilumab was the first biologic for AD, and since its approval, many new treatments have emerged in both late- and early-stage clinical trials. These trials have led to a further understanding of the pathogenesis of AD and to the identification of additional potential therapeutic targets. This review will highlight the emerging therapies and provide approaches on how to choose the right treatment for your patients.
KW - Atopic dermatitis
KW - New systemic treatments
KW - Targeted agent
KW - Treatment options
UR - http://www.scopus.com/inward/record.url?scp=85103635745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103635745&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.02.003
DO - 10.1016/j.jaip.2021.02.003
M3 - Article
C2 - 33838838
AN - SCOPUS:85103635745
SN - 2213-2198
VL - 9
SP - 1449
EP - 1460
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 4
ER -